Guido Franceschini
Franceschini, Guido
![Sudoc [ABES], France](/viaf/images/flags/SUDOC.png "Sudoc [ABES], France")
Franceschini, G.
VIAF ID: 34610090 (Personal)
Permalink: http://viaf.org/viaf/34610090
Preferred Forms
-
200 _ |
‡a
Franceschini
‡b
Guido
-
100 1 _
‡a
Franceschini, G.
-
100 1 0
‡a
Franceschini, G.
-
100 1 _ ‡a Franceschini, G.
-
100 1 _ ‡a Franceschini, Guido
-
100 1 _
‡a
Franceschini, Guido
-
100 1 _
‡a
Franceschini, Guido
(sparse)
-
100 0 _
‡a
Guido Franceschini
4xx's: Alternate Name Forms (4)
Works
| Title | Sources |
|---|---|
| Anti-inflammatory and cardioprotective activities of synthetic high-density lipoprotein containing apolipoprotein A-I mimetic peptides |
|
| Apolipoprotein A-IMilano. Detection of normal A-I in affected subjects and evidence for a cysteine for arginine substitution in the variant A-I |
|
| Apolipoprotein composition and particle size affect HDL degradation by chymase: effect on cellular cholesterol efflux. |
|
| Association of lipoprotein(a) with atherothrombotic events and fibrinolytic variables. A case-control study |
|
| Beta2-adrenergic activity modulates vascular tone regulation in lecithin:cholesterol acyltransferase knockout mice. |
|
| Bezafibrate lowers plasma lipids, fibrinogen and platelet aggregability in hypertriglyceridaemia. |
|
| CETP levels rather than polymorphisms as markers of coronary risk: Healthy athlete with high HDL-C and coronary disease—effectiveness of probucol |
|
| Characterization of A-I-containing lipoproteins in subjects with A-I Milano variant |
|
| Characterization of three kindreds with familial combined hypolipidemia caused by loss-of-function mutations of ANGPTL3. |
|
| Cholesterol efflux from Fu5AH hepatoma cells induced by plasma of subjects with or without coronary artery disease and non-insulin-dependent diabetes: importance of LpA-I:A-II particles and phospholipid transfer protein |
|
| Cholesterol synthesis inhibitors do not reduce Lp(a) levels in normocholesterolemic patients. |
|
| Cimetidine increases HDL-cholesterol, particularly in the HDL3 subfraction |
|
| Clinical Evaluation of Probucol in Hypercholesterolemia: Individual Lipoprotein Responses and Inhibitory Effect on Carotid Atherosclerosis Progression |
|
| Comparison of the lipoprotein and hemostatic changes after a triphasic and a monophasic low dose oral contraceptive in premenopausal middle-aged women |
|
| Denaturation and Self-Association of Apolipoprotein A-I Investigated by Electrophoretic Techniques |
|
| Depletion of pre-beta-high density lipoprotein by human chymase impairs ATP-binding cassette transporter A1- but not scavenger receptor class B type I-mediated lipid efflux to high density lipoprotein |
|
| Distant homology modeling of LCAT and its validation through in silico targeting and in vitro and in vivo assays |
|
| Dose-related increase of HDL-cholesterol levels after N-acetylcysteine in man |
|
| Drug control of reverse cholesterol transport. |
|
| Effect of gemfibrozil treatment in hypercholesterolemia on low density lipoprotein |
|
| Effects of established hypolipidemic drugs on HDL concentration, subclass distribution, and function |
|
| Effects of fenofibrate and simvastatin on HDL-related biomarkers in low-HDL patients |
|
| Elevated soluble cellular adhesion molecules in subjects with low HDL-cholesterol. |
|
| Elevated triglycerides and low HDL cholesterol in transgenic mice expressing human apolipoprotein A-IMilano |
|
| Endogenous hypertriglyceridemia in a nonobese rat model: plasma lipoproteins and dietary sensitivity |
|
| eNOS activation by HDL is impaired in genetic CETP deficiency. |
|
| Enzymatically Active Paraoxonase-1 Is Located at the External Membrane of Producing Cells and Released by a High Affinity, Saturable, Desorption Mechanism |
|
| Familial associations of lipids and lipoproteins in a highly consanguineous population: the Limone sul Garda study |
|
| Familial disorders of plasma apolipoproteins |
|
| Fenofibrate and extended-release niacin improve the endothelial protective effects of HDL in patients with metabolic syndrome. |
|
| Functional LCAT is not required for macrophage cholesterol efflux to human serum |
|
| Gene dose of the epsilon 4 allele of apolipoprotein E and disease progression in sporadic late-onset Alzheimer's disease. |
|
| Genetic determinants of HDL metabolism |
|
| HDL and atherosclerosis: Insights from inherited HDL disorders. |
|
| Human apolipoprotein mutants III : diagnosis and treatment |
|
| Increased carotid artery intima-media thickness in subjects with primary hypoalphalipoproteinemia |
|
| Increased plasma and aortic triglycerides in rabbits after acute administration of 2,3,7,8-tetrachlorodibenzo-p-dioxin |
|
| Increased total and high density lipoprotein cholesterol with apoprotein changes resembling streptozotocin diabetes in tetrachlorodibenzodioxin (TCDD) treated rats. |
|
| Inflammation impairs eNOS activation by HDL in patients with acute coronary syndrome. |
|
| Influence of bezafibrate, fenofibrate, nicotinic acid and etofibrate on plasma high-density lipoprotein levels |
|
| Influence of serum triglycerides on the HDL pattern in normal subjects and patients with coronary artery disease. |
|
| Inhibition of VCAM-1 Expression in Endothelial Cells by Reconstituted High Density Lipoproteins |
|
| Lipoprotein changes and increased affinity of LDL for their receptors after acipimox treatment in hypertriglyceridemia |
|
| Mast cell chymase degrades apoE and apoA-II in apoA-I-knockout mouse plasma and reduces its ability to promote cellular cholesterol efflux |
|
| Mechanisms of high-density lipoprotein reduction after probucol treatment: Changes in plasma cholesterol esterification/transfer and lipase-activities |
|
| Metabolism of apolipoproteins AI and AII in subjects carrying similar apoAI mutations, apoAI Milano and apoAI Paris |
|
| Microporous cholestyramine in suspension form |
|
| Modulated serum activities and concentrations of paraoxonase in high density lipoprotein deficiency states. |
|
| The molecular basis of lecithin:cholesterol acyltransferase deficiency syndromes: a comprehensive study of molecular and biochemical findings in 13 unrelated Italian families |
|
| The molecular structure of apolipoprotein A-II modulates the capacity of HDL to promote cell cholesterol efflux |
|
| Normal vascular function despite low levels of high-density lipoprotein cholesterol in carriers of the apolipoprotein A-I(Milano) mutant |
|
| Novel missense variants in LCAT and APOB genes in an Italian kindred with familial lecithin:cholesterol acyltransferase deficiency and hypobetalipoproteinemia |
|
| Off-target effects of thrombolytic drugs: apolipoprotein A-I proteolysis by alteplase and tenecteplase |
|
| Omacor in familial combined hyperlipidemia: effects on lipids and low density lipoprotein subclasses |
|
| Pantethine reduces plasma cholesterol and the severity of arterial lesions in experimental hypercholesterolemic rabbits |
|
| Pharmacological control of hypertriglyceridemia. |
|
| Pharmacological studies on tiadenol in type IV patients. Evidence for a mechanism of action different from other lipid-lowering drugs |
|
| The plasma concentration of Lpa-I:A-II particles as a predictor of the inflammatory response in patients with ST-elevation myocardial infarction. |
|
| Plasma lecithin:cholesterol acyltransferase and carotid intima-media thickness in European individuals at high cardiovascular risk |
|
| Plasma triglycerides and lipoprotein(a): inverse relationship in a hyperlipidemic Italian population |
|
| Recombinant apolipoprotein A-I(Milano) infusion into rabbit carotid artery rapidly removes lipid from fatty streaks. |
|
| Recombinant apolipoproteins for the treatment of vascular diseases |
|
| Recombinant human LCAT normalizes plasma lipoprotein profile in LCAT deficiency. |
|
| Relation between the HDL apoproteins and AI isoproteins in subjects with the AIMilano abnormality |
|
| Relationship of the phenotypic expression of the A-IMilano apoprotein with plasma lipid and lipoprotein patterns |
|
| Role of LCAT in HDL remodeling: investigation of LCAT deficiency states |
|
| Severe High-Density Lipoprotein Deficiency Associated With Autoantibodies Against Lecithin:Cholesterol Acyltransferase in Non-Hodgkin Lymphoma |
|
| Structural and dynamic features of apolipoprotein A-I cysteine mutants, Milano and Paris, in synthetic HDL. |
|
| Structure and function of the apoA-IV T347S and Q360H common variants |
|
| Synthetic high density lipoproteins for the treatment of myocardial ischemia/reperfusion injury. |
|
| Therapy with HMG CoA reductase inhibitors: characteristics of the long-term permanence of hypocholesterolemic activity |
|
| Tolerability of fibric acids. Comparative data and biochemical bases. |
|
| Vascular alterations in apolipoprotein A-I amyloidosis (Leu75Pro). A case-control study. |
|
| ω-3 Fatty acids selectively raise high-density lipoprotein 2 levels in healthy volunteers |
|
